Please assess the completion status of the following clinical trial:

Trial Title: Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy male or female 18 to 45 years of age at the time of consent~2. BMI of 19-26Kg/m2 and weight of 50-100kg~3. Must provide written informed consent, and in the investigator's opinion, subject is able to understand the nature of the study and any risks involved in participation, and willing to cooperate and comply with the protocol restrictions and requirements~Exclusion Criteria:~1. Subjects who have a medical history of liver, kidney, cardiovascular, nervous / mental, gastrointestinal, respiratory, urinary, endocrine~2. Subjects who have a history of relapse or chronic infection, or a history of acute infection within 2 weeks;~3. Subjects who have previously used anti-IL-12 / 23 or anti-il-23 drugs;~4. Subjects who have clinically significant abnormalities determined by vital signs, physical examination, and laboratory measurements;~5. Subjects who are not suitable for this trial due to other reasons In the investigator' opinion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): IBI112 SC dose1
- Cohort 2 (Type: EXPERIMENTAL): IBI112 SC dose2
- Cohort 3 (Type: EXPERIMENTAL): IBI112 SC dose3
- Cohort 4 (Type: EXPERIMENTAL): IBI112 IV dose4
- Cohort 5 (Type: EXPERIMENTAL): IBI112 IV dose3
- Cohort 6 (Type: EXPERIMENTAL): IBI112 SC dose5
- Cohort 7 (Type: EXPERIMENTAL): IBI112 IV dose5

Based on this trial design, predict the completion outcome and termination type (if applicable).